The prelaunch, market-shaping phase of a product lifecycle can be exciting, especially if you are preparing the market for a major advancement in the field. You have the opportunity to promote your groundbreaking new drug target, formulation, or device and educate the marketplace on how it will improve patient outcomes by meeting the unmet needs associated with a condition. Compelling messages are crafted to tell a story about how the new treatment will effectively fill these gaps, and prelaunch campaigns are developed to deliver that story to healthcare providers (HCPs) in order to build awareness and knowledge.
Is building awareness through education alone enough to change prescribing behavior? It is unlikely, even when a new treatment may seem like the clear choice. When HCPs make a prescribing decision, they use their clinical training and past experiences (their “clinical lens”) to assess the products in their armamentarium vs a new therapy. Here, knowledge (education and awareness) is the key driver.
But when we consider that HCPs are also seeing and interpreting data through their own “behavioral lens”, we realize that information and awareness are not enough to drive them to change their prescribing behaviors. In contrast to the clinical lens, which opens the door to consideration of new ideas, the behavioral lens determines what gets internalized and allows action by processing knowledge in the context of an HCP’s beliefs, perceptions, attitudes, motivations, and skills. How HCPs view a product through their behavioral lens can dictate how open they may be to new data or information and how likely they may be to act on that information. This means that market-shaping efforts need to help data pass through that behavioral lens.
What is the impact of barriers, beliefs, and behaviors?
There are many barriers that may prevent knowledge (ie, data) from passing through that behavioral lens and that need to be addressed to maximize any market-shaping effort. HCPs, like most of us, are habitual creatures. They have ingrained beliefs and entrenched behaviors that drive them to apply mental shortcuts to efficiently operate on a daily basis. These cognitive biases can diminish the impact of new data and limit a provider’s ability to interpret and act on relevant information. This can ultimately lead to continued habitual prescribing and inertia, resulting in poor adoption of new therapies.
Other behavioral factors, like self-efficacy and perceived control, may also impact whether or not an HCP will consider new data or adopt a new product, and thus need to be a key focus of a market-shaping campaign. For example, a lack of self-efficacy may account for a provider being hesitant to prescribe a new, innovative therapy because it requires that they learn how to perform a new skill or procedure that may make them apprehensive or uncomfortable.
Perceived control is a provider’s beliefs about how his/her decisions and actions influence patient outcomes. In many chronic diseases, the burden of management largely falls on the shoulders of the patient. The choices patients make every day, such as what to eat, whether to exercise, and how to manage symptoms, are in their hands. Additionally, patients may feel there are barriers that are preventing them from taking their medication as prescribed. All of these factors may make providers assume that they have limited ability to influence patient outcomes, which may decrease their motivation to act.
How can pharma redefine market shaping?
Optimal market-shaping efforts do more to actively prepare the market to adopt new products by addressing both the clinical and behavioral lenses which ultimately drive HCP prescribing behavior. These efforts go beyond simply providing HCPs with knowledge of an unmet need and how a product will meet that need. They address HCPs’ motivation and skills.
Knowledge is already the focus of most market-shaping campaigns. The need to educate HCPs on current therapeutic options, treatment guidelines, expected outcomes, and relevant data will always be a key component of any market-shaping effort. Knowledge is important, but knowledge alone is often not enough.
Motivation is a key driver of behavior change. Sometimes knowledge of unmet needs and burdens can help provide motivation to adopt a new therapy that addresses these, but motivation alone is also not enough to change behavior. To break through habitual prescribing and inertia, we need to address behavioral factors like perceived control and cognitive biases.
We need to help providers become self-aware of how they practice and how they perceive their patients. By doing this, we can drive increased perceived value in a new therapy and motivation to prescribe.
Using behavioral science to drive motivation. Cognitive debiasing techniques such as bias inoculation and cognitive forcing can be applied in practical ways or in practical learning situations. These experiences guide providers through scenarios where they can analyze their decision-making and work through a deliberate thought process and consideration of alternatives. These techniques help providers stop and think and can open the door to new ways of thinking.
Skills can often refer to the need to learn how to perform a new procedure or use a new device. But we need to go beyond the procedural and think about that behavioral lens. We may need to help HCPs with other skills that will ultimately impact the success of a product launch. These may include ensuring providers
Using behavioral science to build skills. Implementing active learning into promotional activities or training can be one way to help build procedural skills. But we need to do more to help equip providers to look outside the box and break through their biases. For example, helping providers build communication skills by showing them how to use techniques like motivational interviewing or to apply shared decision-making in its true form can help them identify patients who may not be optimized on treatment and/or appreciate individual patient preferences.
Behavioral science provides a roadmap to understanding how HCPs make decisions and what drives prescribing behavior, but also, more importantly, it gives us strategies that we can apply to disrupt the status quo. By addressing knowledge, motivation, and skills, market-shaping campaigns can work harder and smarter to begin to shift provider behavior before a product even becomes available and allow for accelerated uptake at launch.
MicroMass delivers behavior change experiences for our clients by combining proven, evidence-based techniques and compelling creative. See the difference.